Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification

Stock Information for Delcath Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Delcath Systems Inc.

Delcath Systems Announces Ratio for Reverse Stock Split
Delcath Systems to Present at the MicroCap Rodeo Investor Conference
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems Announces Presentation at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright
Delcath Systems Closes $9.5 Million Private Placement
Delcath Systems Announces $9.5 Million Private Placement
Delcath Enhances Board of Directors With Appointment of Commercial Leader, John R. Sylvester
Results of Single Center Study on Delcath's PHP Therapy Published in Cancer Imaging

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.